Condition: High Grade Glioma · CNS Tumor · Sponsor: St. Jude Children's Research Hospital
This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.
This description comes directly from the study's public registry record.
Tabatha E. Doyle, RN · 901-595-2544 · tabatha.doyle@stjude.org
Daniel Moreira, MD, MEd · 901-585-1911 · daniel.moreira@stjude.org
Always discuss trial participation with your own doctor first.
| St. Jude Children's Research Hospital | Memphis, Tennessee, United States | Recruiting |
| Hospital de Câncer de Barretos | Barretos, São Paulo, Brazil | Recruiting |
| GRAACC Hospital (Grupo de Apoio ao Adolescente e à Criança com Câncer) | São Paulo, Brazil | Recruiting |
| Hospital Santa Marcelina | São Paulo, Brazil | Recruiting |
| King Hussein Cancer Center | Amman, Jordan | Recruiting |
| Instituto Nacional de Enfermedades Neoplásicas | Lima, Peru | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06528691